A Phase 1 interventional study of Etelcalcetide and Placebo in Secondary Hyperparathyroidism, sponsored by Amgen. Completed at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-10.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary — 2 open to participants now, 2 under way, 2 of them phase 3. etelcalcetide · Hyperparathyroidism, Secondary.
Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 1, and was the 13th registered.
188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.
Browse Hyperparathyroidism, Secondary studies →2 of the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in Belgium, Czechia, France and 9 more countries
Ages 2–17
Amgen · Sites in United States, Argentina, India and 7 more countries
Ages 0–18
By country, each count listing its studies:
etelcalcetide: first FDA approval 2017 (PARSABIV), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2018.
This study's enrollment of 33 is below the median of 62 across 146 interventional studies indexed under Hyperparathyroidism, Secondary.
Median enrollment 72 across the 16 interventional studies. Of the 14 that completed or were terminated, 14 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 2 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
33 studies in Hyperparathyroidism, Secondary by Amgen: 2 open now, 2 under way, 2 of them phase 3. Of 31 finished, 22 (71%) have results posted.
Among the 33 studies in Hyperparathyroidism, Secondary by Amgen, this one is the 25th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 1, and was the 30th registered.
Amgen’s Hyperparathyroidism, Secondary studies by the year they started, since 2001.
1 of the studies testing etelcalcetide in Hyperparathyroidism, Secondary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 33 in Hyperparathyroidism, Secondary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a multiple-dose, double-blind, randomized, placebo-controlled study. Chinese subjects residing in Mainland China with chronic kidney disease (CKD) receiving hemodialysis were randomized in a 3:1 ratio to receive 5 mg intravenous (IV) of etelcalcetide or placebo 3 times a week (TIW) for approximately 4 weeks, with a subsequent follow up period of approximately 4 weeks.
Doses were given at the end of each scheduled hemodialysis session on study days 1 through day 27 and subject participation was complete after day 55 end-of-study (EOS) procedures were performed. Doses were administered TIW for 4 weeks, for a total of 12 doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Female subject of not willing to use a(n) acceptable method(s) of effective during treatment with AMG 416, and for an additional 3 months after the end of treatment with AMG 416. Female subjects who have had a hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal ligation, or who are are not required to use contraception. Postmenopausal is defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
Drug: Placebo
5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
Drug: Etelcalcetide
Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
Also known as: AMG 416
Placebo supplied to match active intervention.
Pharmacokinetic (PK) Parameter: Time to Maximum Drug Concentration (Tmax) of Plasma Etelcalcetide on Days 1 and 27
Tmax is the time to maximum drug concentration of plasma etelcalcetide after dosing on Days 1 and 27.
Time frame: Days 1 and 27; PK blood sampling predialysis, and at 10, 30, 60, 90 min postdose, as well as on Day 2 and 28 between 18 and 30 hours after study drug administration
PK: Maximum Observed Drug Concentration (Cmax) of Plasma Etelcalcetide on Days 1 and 27
Cmax was defined as the maximum observed plasma drug concentration measured between the time of drug administration to the beginning of the next dialysis session.
Time frame: Days 1 and 27; PK blood sampling predialysis, and at 10, 30, 60, 90 min postdose, as well as on Day 2 and 28 between 18 and 30 hours after study drug administration
Pharmacokinetic (PK) Parameter: Area Under the Curve From Time Zero to the Beginning of the Subsequent Hemodialysis Treatment (AUClast) of Plasma Etelcalcetide on Days 1 and 27
AUClast was specifically defined in this study as the area under the concentration time curve measured from the time of drug administration to the beginning of the next dialysis session, following the first and last dose.
Time frame: Days 1 and 27; PK blood sampling predialysis, and up to 44-50 hour postdose.at 10, 30, 60, 90 min postdose: Day 2 and 28 between 18 and 30 hours after study drug administration; Day 3 (predialysis) + Day 29
Pharmacokinetic (PK) Parameter: Accumulation Ratio Comparing Days 1 and 27
Accumulation ratio, calculated as AUClast day 27/AUClast day 1.
Time frame: Days 1 and 27; PK blood sampling predialysis, and up to 44-50 hour postdose.at 10, 30, 60, 90 min postdose: Day 2 and 28 between 18 and 30 hours after study drug administration; Day 3 (predialysis) + Day 29
Participants With Treatment-Emergent Adverse Events (TEAEs)
The severity of each adverse event was assessed using the NCI-CTCAE Version 4.0 according to the following: * Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated * Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) * Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL * Grade 4 - Life-threatening * Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.
Time frame: Day 1 up to Day 55 (end of study)
Participants With Treatment-Emergent Adverse Events (TEAEs) of Interest
Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. Narrow search criteria used for both standardized MedDRA queries (SMQ) and events of interest (EOI). One preferred term (PT) could match multiple EOIs. Infusion Reaction EOI counts included only those events which had onset day coinciding with study medication infusion and resolved on the same day or the day after onset.
Time frame: Day 1 up to Day 55 (end of study)
Participants With Clinically-Significant Changes in Electrocardiograms (ECGs) From Baseline to End of Study
Count of participants who exhibited a clinically significant change in the results of their 12-lead electrocardiograms (ECG) when comparing baseline to end of study ECGs.
Time frame: Baseline is Day -2; End of Study is Day 55
Change From Baseline to End of Study in Weight
Change from baseline in weight measured at visit.
Time frame: Day 1 up to Day 55
Change From Baseline to End of Study in Systolic and Diastolic Blood Pressures
Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.
Time frame: Baseline Day 1 prior to dialysis; End of Study is Day 55
Baseline and Change From Baseline to End of Study in Heart Rate
Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.
Time frame: Baseline Day 1 prior to dialysis; End of Study is Day 55
Change From Baseline to End of Study in Calcium
Calcium was tested at a central laboratory.
Time frame: Baseline is Day 1 prior to dialysis; End of Study is Day 55
Change From Baseline to End of Study in Corrected Calcium (cCa)
Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8
Time frame: Baseline is the average of Day -2 and Day 1 prior to dialysis; End of Study is Day 55
Participants With Low Corrected Calcium (cCA) By Category
The lowest cCA value for each participant is reported. Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8
Time frame: Timeframes: Days 8, 15, 22, 27, 29, 34, 41, 55
Baseline and Change From Baseline to End of Study in Serum Albumin
Serum albumin was tested at a central laboratory.
Time frame: Baseline is the average of Day -2 and Day 1 prior to dialysis; End of Study is Day 55
Change From Baseline to End of Study in Serum Phosphorus
Serum phosphorus was tested at a central laboratory.
Time frame: Baseline is Day 1 prior to dialysis; End of Study is Day 55
Participants With Anti-etelcalcetide Antibody at Baseline and Postbaseline
Participants with positive titers for antibodies to etelcalcetide could be asked to return to the clinical research unit to provide additional serum samples.
Time frame: Baseline: Day 1 prior to dialysis. Postbaseline: Days 29 and 55 prior to dialysis
This study was conducted at 5 centers in China.
| Milestone | Placebo | Etelcalcetide |
|---|---|---|
| Started | 8 | 25 |
| Completed | 8 | 24 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Tmax is the time to maximum drug concentration of plasma etelcalcetide after dosing on Days 1 and 27.
| hour | Placebo | Etelcalcetide |
|---|---|---|
| Day 1 | — | 0.22 (0.17 to 0.27) |
| Day 27 | — | 0.22 (0.17 to 0.25) |
Cmax was defined as the maximum observed plasma drug concentration measured between the time of drug administration to the beginning of the next dialysis session.
| ng/mL | Placebo | Etelcalcetide |
|---|---|---|
| Day 1 | — | 216 ± 157 |
| Day 27 | — | 236 ± 53.7 |
AUClast was specifically defined in this study as the area under the concentration time curve measured from the time of drug administration to the beginning of the next dialysis session, following the first and last dose.
| hour*ng/mL | Placebo | Etelcalcetide |
|---|---|---|
| Day 1 | — | 1110 ± 311 |
| Day 27 | — | 3310 ± 893 |
Accumulation ratio, calculated as AUClast day 27/AUClast day 1.
| ratio | Placebo | Etelcalcetide |
|---|---|---|
| Pharmacokinetic (PK) Parameter: Accumulation Ratio Comparing Days 1 and 27 | — | 3.02 ± 0.607 |
The severity of each adverse event was assessed using the NCI-CTCAE Version 4.0 according to the following: * Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated * Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) * Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL * Grade 4 - Life-threatening * Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.
| Participants | Placebo | Etelcalcetide |
|---|---|---|
| All TEAEs | 7 | 25 |
| TEAEs Grade >= 3 | 0 | 5 |
| TEAEs Grade >= 4 | 0 | 1 |
| Serious TEAEs | 0 | 3 |
| TEAEs leading to study treatment discontinuation | 0 | 0 |
| Fatal TEAEs | 0 | 0 |
| Treatment-related TEAEs | 1 | 18 |
| Treatment-related TEAEs Grade >= 3 | 0 | 1 |
| Treatment-related TEAEs Grade >= 4 | 0 | 0 |
| Treatment-related serious TEAEs | 0 | 1 |
| Trt-related TEAEs leading to study trt discon | 0 | 0 |
| Treatment-related Fatal TEAEs | 0 | 0 |
Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. Narrow search criteria used for both standardized MedDRA queries (SMQ) and events of interest (EOI). One preferred term (PT) could match multiple EOIs. Infusion Reaction EOI counts included only those events which had onset day coinciding with study medication infusion and resolved on the same day or the day after onset.
| Participants | Placebo | Etelcalcetide |
|---|---|---|
| Adynamic bone (EOI) | 0 | 0 |
| Cardiac Failure (EOI) | 0 | 0 |
| Convulsions (SMQ) | 0 | 0 |
| Fractures (EOI) | 0 | 0 |
| Hypersensitivity (SMQ) | 0 | 5 |
| Dermatitis allergic (PT) | 0 | 2 |
| Rash (PT) | 0 | 2 |
| Dermatitis (PT) | 0 | 1 |
| Hypocalcemia (EOI) | 0 | 11 |
| Blood calcium decreased (PT) | 0 | 10 |
| Hypocalcaemia (PT) | 0 | 2 |
| Hypophosphatemia (EOI) | 0 | 0 |
| Infusion reaction (EOI) | 0 | 1 |
| Hypotension (PT) | 0 | 1 |
| Torsade de pointes-QT prolongation (SMQ) | 0 | 0 |
| Ventricular tachyarrhythmias (SMQ) | 0 | 0 |
Count of participants who exhibited a clinically significant change in the results of their 12-lead electrocardiograms (ECG) when comparing baseline to end of study ECGs.
| Participants | Placebo | Etelcalcetide |
|---|---|---|
| Normal Baseline / Abnormal End of Study | 0 | 2 |
| Abnormal Baseline / Normal End of Study | 0 | 1 |
| No Change in Baseline to End of Study | 8 | 21 |
Change from baseline in weight measured at visit.
| kg | Placebo | Etelcalcetide |
|---|---|---|
| Change From Baseline to End of Study in Weight | 1.32 ± 0.79 | 0.76 ± 1.39 |
Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.
| mmHg | Placebo | Etelcalcetide |
|---|---|---|
| Systolic Blood Pressure | 1.1 ± 15.5 | 6.1 ± 18.6 |
| Diastolic Blood Pressure | 4.4 ± 9.2 | 1.5 ± 11.9 |
Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.
| beats/minute | Placebo | Etelcalcetide |
|---|---|---|
| Baseline | 79.5 ± 8.3 | 82.8 ± 13.8 |
| Change from Baseline to End of Study | -2.9 ± 6.5 | -1.4 ± 8.9 |
Calcium was tested at a central laboratory.
| mmol/L | Placebo | Etelcalcetide |
|---|---|---|
| Change From Baseline to End of Study in Calcium | -0.10 ± 0.11 | -0.07 ± 0.12 |
Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8
| mmol/L | Placebo | Etelcalcetide |
|---|---|---|
| Change From Baseline to End of Study in Corrected Calcium (cCa) | -0.08 ± 0.10 | -0.05 ± 0.10 |
The lowest cCA value for each participant is reported. Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8
| Participants | Placebo | Etelcalcetide |
|---|---|---|
| Participants with cCA < 1.75 mmol/L | 0 | 0 |
| Participants with cCA 1.75 to < 1.87 mmol/L | 0 | 1 |
| Participants with cCA 1.87 to < 2.07 mmol/L | 0 | 12 |
Serum albumin was tested at a central laboratory.
| g/dL | Placebo | Etelcalcetide |
|---|---|---|
| Baseline | 41.20 ± 2.37 | 39.37 ± 2.79 |
| Change from Baseline to End of Study | -1.06 ± 1.81 | -0.59 ± 2.13 |
Serum phosphorus was tested at a central laboratory.
| mmol/L | Placebo | Etelcalcetide |
|---|---|---|
| Change From Baseline to End of Study in Serum Phosphorus | -0.03 ± 0.53 | -0.06 ± 0.56 |
Participants with positive titers for antibodies to etelcalcetide could be asked to return to the clinical research unit to provide additional serum samples.
| Participants | Placebo | Etelcalcetide |
|---|---|---|
| Binding antibody positive at or before baseline | — | 1 |
| Positive postbaseline/negative baseline | — | 0 |
| Transient, i.e. negative at last timepoint tested | — | 0 |
Collected over Day 1 up to Day 55 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Etelcalcetide | 0/25 (0%) | 3/25 (12%) | 22/25 (88%) |
| Event | Placebo | Etelcalcetide |
|---|---|---|
| PneumoniaInfections and infestations | 0/8 | 1/25 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/8 | 1/25 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/8 | 1/25 |
| Event | Placebo | Etelcalcetide |
|---|---|---|
| Blood calcium decreasedInvestigations | 0/8 | 10/25 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/8 | 0/25 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/8 | 4/25 |
| PruritusSkin and subcutaneous tissue disorders | 1/8 | 4/25 |
| HypotensionVascular disorders | 0/8 | 4/25 |
| ArrhythmiaCardiac disorders | 1/8 | 0/25 |
| Eye disorderEye disorders | 1/8 | 0/25 |
| ConstipationGastrointestinal disorders | 1/8 | 1/25 |
| ContusionInjury, poisoning and procedural complications | 1/8 | 0/25 |
| Limb injuryInjury, poisoning and procedural complications | 1/8 | 0/25 |
Safety analysis set consisting of all participants who received at least 1 dose of investigational product.
| Age, Continuous(years) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 49.8 ± 12.5 | 50.2 ± 11.4 | 50.1 ± 11.5 |
| Sex: Female, Male(Participants) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| Female | 3 | 10 | 13 |
| Male | 5 | 15 | 20 |
| Race (NIH/OMB)(Participants) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 25 | 33 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Height(cm) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 167.54 ± 8.17 | 164.48 ± 7.68 | 165.22 ± 7.79 |
| Weight(kg) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 65.74 ± 8.45 | 67.71 ± 13.53 | 67.24 ± 12.40 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 23.64 ± 3.03 | 24.98 ± 4.03 | 24.65 ± 3.81 |
| Systolic Blood Pressure(mmHg) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 139.25 ± 27.37 | 141.24 ± 19.39 | 140.76 ± 21.13 |
| Diastolic Blood Pressure(mmHg) | Placebo | Etelcalcetide | Total |
|---|---|---|---|
| Mean | 80.38 ± 13.54 | 81.68 ± 13.00 | 81.36 ± 12.93 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2018 to primary completion in Feb 2019, 11 months.
Results were first posted in Feb 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etelcalcetide
Hyperparathyroidism, Secondary →